EP0346830A3
Use of opiate antagonists for the preparation of a pharmaceutical composition for the treatment of alcoholism
Abstract
Described is the use of opiate antagonists for the preparation of pharmaceutical compositions to be administered simultaneously or separately sequentially with alcohol in the treatment of alcoholism. These pharmaceutical compositions are capable of extinguishing the alcohol-drinking response of alcoholics during a relatively short period of time by having the alcoholics drink alcoholic beverages repeatedly while the opiate antagonist contained in said pharmaceutical composition blocks the positive reinforcement effects of ethanol in the brain.
Term
Term ended
Projected expiry passed 13 June 2009, 17.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EP0019423A1 | Cites | European Patent Office (EPO) | Search report |
| US3966940A | Cites | United States of America | Search report |
12 members in 7 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 205758 | United States of America | – | |
| 20575888 | United States of America | A | |
| 20575888 | United States of America | A | |
| US19880205758 | – | – | – |
Members12
| Document | Office | Kind | |
|---|---|---|---|
| US4882335A | United States of America | A | |
| AU3634889A | Australia | A | |
| EP0346830A2 | European Patent Office (EPO) | A2 | |
| AU609310B2 | Australia | B2 | |
| EP0346830A3This record | European Patent Office (EPO) | A3 | |
| EP0346830B1 | European Patent Office (EPO) | B1 | |
| AT122231T | Austria | T | |
| ATE122231T1 | Austria | T1 | |
| DE68922525D1 | Germany | D1 | |
| CA1336962C | Canada | C | |
| ES2074454T3 | Spain | T3 | |
| DE68922525T2 | Germany | T2 |
55 legal events, as 5 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Nl: ceased due to reaching the maximum lifetime of a patentCeasedNLV7 | NLV7 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| Nl: decision of oppositionOppositionNLR2 | NLR2 | EP | |
| Transfer of patentPC2A | PC2A | ES | |
| Nl: assignments of ep-patentsNLS | NLS | EP | |
| Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1NLT1 | NLT1 | EP | |
| Opposition proceedings terminatedOpposition27C | 27C | EP | |
| Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)732E | 732E | GB | |
| Name/firm changedALKO LIMITED TRANSFER- ALKO GROUP LTD.PFA | PFA | CH | |
| AssignmentPUE | PUE | CH | |
| Termination of opposition procedure: date of legal effect publishedOppositionORIGINAL CODE: 0009276PLBM | PLBM | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: OPPOSITION PROCEDURE CLOSEDSTAA | STAA | EP | |
| Be: change of holder971215 *CONTRAL CLINICS OYBECH | BECH | EP | |
| Opposition procedure terminatedOppositionORIGINAL CODE: EPIDOS OPPCPLBL | PLBL | EP | |
| Reply of patent proprietor to notice(s) of oppositionOppositionORIGINAL CODE: EPIDOS OBSOPLBF | PLBF | EP | |
| Reply of patent proprietor to notice(s) of oppositionOppositionORIGINAL CODE: EPIDOS OBSOPLBF | PLBF | EP | |
| Nl: opposition has been filed with the epoOppositionNLR1 | NLR1 | EP | |
| Reply of patent proprietor to notice(s) of oppositionOppositionORIGINAL CODE: EPIDOS OBSOPLBF | PLBF | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Validation in greece3016513FG4A | FG4A | GR | |
| Fr: translation filedET | ET | EP | |
| Corresponds to:REF | REF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0346830
- Publication, DOCDB
- 0346830
- Publication, EPODOC
- EP0346830
- Application
- 110688
- Application, DOCDB
- 89110688
- Application, EPODOC
- EP19890110688
Titles3
- German
- Verwendung von Opium-Antagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Alkoholismus
- English
- Use of opiate antagonists for the preparation of a pharmaceutical composition for the treatment of alcoholism
- French
- Utilisation des antagonistes des opiates pour obtenir une composition pharmaceutique de traitement de l'alcoolisme
Classification
- CPC, 2
- A61K31/00
- A61K31/485
- IPC, 2
- A61K31 00
- A61K31 485
Designated states1
- Contracting states, 1
- Sweden